There may be a role for new cardiovascular biomarkers, namely, mid-regional proadrenomedullin (MR-proADM) and mid-regional proartrial natriuretic peptide (MR-proANP), to predict mortality in critically ill patients with pneumonia. This evidence concerns the gene NPPA and pneumonia.